Dicyclomine: Nursing Drug Guide, Anticholinergic Toxicity & NCLEX Review
Healthcare medication guide: before every dose, screen anticholinergic burden, urinary retention, and ileus risk—then watch for confusion, hot dry skin, and absent sweating in heat, especially in older adults on functional bowel/IBS therapy up to 160 mg/day.
Never give dicyclomine to infants under 6 months or to breastfeeding mothers. U.S. labeling reports serious respiratory events, seizures, and death in infants exposed to dicyclomine. In adults, anticholinergic toxicity can present as confusion, delirium, urinary retention, constipation, ileus, tachycardia, blurred vision, dry mouth, and hot flushed dry skin with decreased sweating—with heat stroke risk in hot environments. Hold the drug, review total anticholinergic load (including diphenhydramine, TCAs, and bladder antispasmodics), and escalate per facility protocol.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first dicyclomine dose, confirm no contraindicated obstructive GI or urinary disease, glaucoma, or myasthenia gravis, and total anticholinergic burden on the MAR. If an older adult develops confusion, urinary retention, abdominal distension, or hot dry skin without sweating, treat as possible anticholinergic toxicity until ruled out.
Most common brand names
Oral tablets, capsules, and syrup formulations are available; some products also supply intramuscular injection. Verify strength (10 mg, 20 mg, or 40 mg) and route on every pass—oral and parenteral products are not interchangeable without prescriber and pharmacy review.
Common U.S. brand names include Bentyl and generic dicyclomine hydrochloride. The United Kingdom lists dicycloverine as an alternate name for the same antispasmodic class.
Why we give it — Indications
Per current U.S. prescribing information, dicyclomine is indicated for patients with functional bowel / irritable bowel syndrome—relief of smooth-muscle spasm in the gastrointestinal tract. It is not a primary therapy for infectious or inflammatory diarrhea; those pathways require diagnosis and targeted treatment.
MedlinePlus and product labeling describe dicyclomine as an anticholinergic that blocks activity of a natural substance in the body to relieve GI tract muscle spasm. Nurses should align expected outcomes with cramping and bowel-pattern goals rather than musculoskeletal spasm relief.
| Use | Detail |
|---|---|
| Irritable bowel syndrome | Functional bowel disorder with abdominal pain and altered bowel habits |
| Functional GI spasm | Adjunct for cramping related to abdominal pain when prescriber selects antispasmodic therapy |
| Reassessment | Discontinue if not effective within 2 weeks or if side effects require <80 mg/day per labeling |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Dicyclomine is an antispasmodic and anticholinergic (antimuscarinic) agent. Peripheral effects follow inhibition of muscarinic receptors: reduced GI motility, dry mouth, mydriasis, tachycardia, urinary hesitancy, and decreased sweating. In high environmental temperature, heat prostration (fever and heat stroke from decreased sweating) can occur—discontinue and support per labeling if symptoms develop.
Dosing overview
Oral dosing is individualized. After one week at the starting dose, escalation is allowed only if anticholinergic side effects permit. Discontinue if the patient cannot tolerate at least 80 mg per day after two weeks or if efficacy is not achieved.
| Scenario | Dose adjustment (labeling) |
|---|---|
| Elderly | Use caution; start at low end of adult range; greater sensitivity to adverse effects |
| Renal impairment | Careful dose selection; monitor renal function per labeling geriatric guidance |
| Hepatic impairment | Not specified in the reviewed prescribing information for dedicated adjustment—use caution and monitor clinically |
| Infants <6 months | Contraindicated |
| Pediatrics ≥6 months | Not specified in the reviewed prescribing information for routine pediatric IBS dosing—follow specialist orders only |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: If a dose is missed, take when remembered unless almost time for the next dose—do not double doses per MedlinePlus counseling. Repeated extra doses increase anticholinergic toxicity risk.
Before you give it — Safety check
Pretreatment checks
- Complete medication reconciliation for total anticholinergic load (diphenhydramine, amitriptyline, bladder antispasmodics, glycopyrrolate)
- Confirm age ≥6 months and patient is not breastfeeding
- Screen for obstructive GI disease, severe ulcerative colitis, reflux esophagitis, and ileus risk
- Assess urinary retention history, BPH, and ability to void
- Review glaucoma and myasthenia gravis—contraindicated per labeling
- Plan fall-risk precautions, heat precautions, and sedation checks in older adults
Contraindications
- Hypersensitivity to dicyclomine or formulation ingredients
- Infants less than 6 months of age
- Nursing mothers
- Obstructive uropathy; obstructive disease of the gastrointestinal tract
- Severe ulcerative colitis; reflux esophagitis
- Unstable cardiovascular status in acute hemorrhage
- Glaucoma; myasthenia gravis (except specialized anticholinesterase-adjunct use per labeling—not routine nursing administration)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Other anticholinergics (atropine, antihistamines, TCAs) | Additive dry mouth, confusion, retention, ileus, tachycardia | Calculate anticholinergic burden; hold and notify if toxicity signs appear |
| Antacids | May interfere with absorption of anticholinergic agents per labeling | Separate timing per pharmacy; do not start antacids without review |
| MAO inhibitors, antipsychotics, antiarrhythmics Class I | Listed as drugs that may increase anticholinergic side effects | Reconcile on admission; monitor mental status and autonomic signs |
| Digoxin (slow-dissolve forms) | Anticholinergics may slow GI motility and raise serum digoxin | Monitor digoxin level and clinical toxicity per prescriber plan |
| Alcohol and CNS depressants | Additive drowsiness and impaired psychomotor function | Fall precautions; teach avoidance of alcohol; coordinate pain assessment for cramping |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral route: Give tablets, capsules, or syrup around the same times daily (typically four times daily). Syrup requires accurate oral measurement per pharmacy.
- Verify product strength (10 mg, 20 mg, or 40 mg) and running 24-hour total—especially after dose increases at week 1
- Take with or without food unless pharmacy directs otherwise; drowsiness or blurred vision may affect timing of activities
- Separate from antacids per pharmacy if both are ordered
- Chart formulation and dose changes on handoff—look-alike strengths are a common error source
Expected therapeutic response
- Reduced GI cramping and improved comfort with functional bowel/IBS symptoms when antispasmodic therapy is appropriate
- Reassess within two weeks—labeling directs discontinuation if efficacy is not achieved
- Mild dry mouth or drowsiness may occur early—worsening constipation, inability to void, or mental status change suggests anticholinergic toxicity
Red flags — Stop and act
Escalate immediately for suspected anticholinergic toxicity, heat stroke, ileus, or overdose.
- Anticholinergic crisis: hot flushed dry skin, absent sweating, fever, confusion, hallucinations, agitation, tachycardia—hold dicyclomine and cool/support per protocol
- Urinary retention: suprapubic discomfort, inability to void, rising bladder scan—notify prescriber; avoid further anticholinergics
- Ileus / toxic megacolon risk: severe abdominal distension, absent bowel sounds, vomiting—especially with ulcerative colitis history
- Overdose: dilated pupils, dry mouth, CNS stimulation, convulsions, neuromuscular weakness—activate emergency pathway and contact poison control/toxicology per facility protocol
- Any exposure in an infant <6 months or breastfed infant—emergency evaluation regardless of dose
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Dry mouth | Most frequent anticholinergic effect in clinical trials (~61% any anticholinergic-type AE at 160 mg/day) | Oral care; hydration; swallow assessment |
| Dizziness, drowsiness, blurred vision | Common CNS/ophthalmic effects per labeling | Fall precautions; avoid driving until response known |
| Constipation, nausea, abdominal distension | Reduced GI motility | Bowel regimen; monitor for ileus; review other anticholinergics |
| Urinary hesitancy / retention | More likely with prostatic hypertrophy | Intake/output; bladder scan; hold if unable to void |
| Confusion, delirium, hallucinations | Reported especially in elderly or psychiatric illness; often resolves within 12–24 h after stop | Hold drug; neuro checks; reduce anticholinergic load |
| Decreased sweating / heat intolerance | Heat prostration and heat stroke risk in high temperatures | Cooling measures; discontinue in hot environment per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdose signs per U.S. prescribing information include headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dry mouth, difficulty swallowing, and CNS stimulation including convulsions. A curare-like neuromuscular blockade (weakness, possible paralysis) may occur.
Management (labeling)
- Gastric lavage, emetics, and activated charcoal when appropriate
- Short-acting barbiturates or benzodiazepines for marked excitement
- If indicated, an appropriate parenteral cholinergic agent may be used as an antidote
- Supportive care and monitoring for apnea and neuromuscular weakness
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance for suspected overdose—especially with altered mental status, seizures, or respiratory depression.
Look-alike / sound-alike and error prevention
- Dicyclomine vs dicycloverine, cyclobenzaprine, diclofenac—read back full generic name on verbal/telephone orders
- Bentyl 10 mg vs 20 mg vs 40 mg—independent double-check strength and QID schedule
- 20 mg QID vs 20 mg daily—common scheduling error; verify total daily dose (up to 160 mg)
- Syrup vs tablet—use pharmacy oral syringe; do not substitute household spoons
- Home antihistamine PRN not on MAR—hidden anticholinergic load is a frequent toxicity trigger
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Anticholinergic screen | Ask about bladder meds, allergy pills, sleep aids, and eye drops—even OTC |
| Voiding check | Post-void residual or intake/output after first doses in men with BPH or any retention history |
| Heat plan | In warm units or summer discharges, teach decreased sweating risk; encourage fluids and cooling |
| Two-week stop | Flag continued orders if cramping unchanged or patient cannot tolerate 80 mg/day minimum |
| Commonly missed | PRN diphenhydramine plus scheduled dicyclomine; giving syrup with wrong mL conversion |
| Ask pharmacy when | Antacid timing, anticholinergic burden tools, or cholinergic antidote availability for severe toxicity |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Greater anticholinergic sensitivity—confusion, falls, retention; cautious dosing at low end of range |
| Prostatic hypertrophy | Urinary retention risk—monitor voiding closely |
| Inflammatory bowel disease | Contraindicated in severe ulcerative colitis; ileus and toxic megacolon risk if motility suppressed |
| Cardiovascular instability | Contraindicated in unstable cardiovascular status during acute hemorrhage |
| Pregnancy | Pregnancy Category B; adequate human data at 80–160 mg/day not available—use only if clearly needed |
| Lactation | Contraindicated—excreted in milk; serious infant reactions possible per labeling and LactMed |
| Infants <6 months | Contraindicated—reports of apnea, respiratory collapse, seizures, and death |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Abdominal cramping, bowel pattern, and tolerance of oral intake
- Mental status, especially in older adults—confusion or hallucinations
- Voiding pattern, bladder distension, and bowel sounds
- Heart rate, blood pressure, temperature, and skin moisture in warm environments
- Dry mouth, vision changes, dizziness, and fall incidents
- Total anticholinergic medicines on the profile after each reconciliation
Document
- Formulation, strength, dose, route, time, and running 24-hour total
- Contraindication screen (age, breastfeeding, glaucoma, obstructive GI/urinary disease) before first dose
- Hold events, inability to void, ileus concerns, and prescriber/pharmacy notifications
- Patient teaching on heat exposure, alcohol avoidance, and toxicity symptoms
Patient teaching
- Tell your care team about all allergy, sleep, and bladder medicines—including over-the-counter products
- This medicine reduces stomach cramping but can cause dry mouth, constipation, and drowsiness
- Do not drive or operate machinery until you know how it affects you; alcohol increases drowsiness
- In hot weather you may sweat less—stay cool, drink fluids, and report fever or feeling overheated
- Report inability to urinate, severe belly bloating, confusion, fast heartbeat, or vision changes immediately
- Do not take extra doses—call the team if cramping is not better after two weeks
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Infant under 6 months, breastfeeding, or suspected exposure in either group
- Contraindicated conditions: obstructive GI or urinary disease, severe ulcerative colitis, reflux esophagitis, glaucoma, myasthenia gravis, unstable cardiovascular status in acute hemorrhage
- Suspected anticholinergic toxicity: hot dry skin, absent sweating with fever, acute confusion, urinary retention, ileus, tachycardia with altered mental status
- Unable to tolerate at least 80 mg per day after two weeks or no therapeutic benefit per labeling stop rule
- Planned antacid start without pharmacy spacing plan for absorption interaction
- Severe drowsiness, syncope, or inability to arouse
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
On GI and med-surg units, dicyclomine is often ordered for “stomach cramps” without a structured anticholinergic review. Build anticholinergic burden screening into the same workflow as opioid and high-alert checks.
1. Check-before-you-give protocol
- Right patient, drug, strength, route, and time—confirm not an infant <6 months and not breastfeeding
- Contraindication screen for obstructive GI/urinary disease, glaucoma, and myasthenia gravis
- Home and inpatient anticholinergics reconciled—including PRN allergy and sleep medicines
2. High-alert and safety badge
Not a universal high-alert drug, but anticholinergic toxicity and infant exposure can be life-threateningTreat infant contraindication, breastfeeding prohibition, and acute confusion/retention with the same rigor as high-alert medications: independent review and clear handoff language.
3. Clinical workflow: hold and question rules
- If diphenhydramine or another anticholinergic is started, hold dicyclomine until prescriber/pharmacy documents plan
- If patient cannot void after dose, hold and assess retention before next dose
- If no IBS relief after two weeks or dose must stay below 80 mg/day, question continued need
4. Critical teach-back questions
- “What medicines must you tell us about before taking this antispasmodic?” (Allergy pills, bladder meds, sleep aids.)
- “What symptoms mean you should call right away?” (Cannot urinate, severe bloating, confusion, fever without sweating.)
5. Care coordination
Pharmacist: Anticholinergic burden review, antacid spacing, overdose and cholinergic antidote guidance
Prescriber / dietitian: IBS plan, fiber and trigger counseling, alternative agents if anticholinergic risk prohibits dicyclomine
🧠 Quick mental checklist
- Patient ≥6 months and not breastfeeding?
- Any hidden anticholinergic on the profile?
- Can the patient void and are bowel sounds present?
- Any hot dry skin, confusion, or fever without sweating?
- Has therapy reached the two-week efficacy review point?
Dicyclomine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for dicyclomine with a tabbed IBS case (MAR, vitals, history, nursing notes) on an older adult with hidden anticholinergic load, then priority action, anticholinergic cue recognition, deterioration trends, documentation cloze, overdose judgment, and matrix urgency—recognize cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, vitals, history, and nursing note details for this case.
- Dicyclomine 20 mg PO QID — day 3; 0800 and 1200 given; 1600 held after assessment
- Diphenhydramine 25 mg PO at bedtime PRN — given 2200 last night for itching (not on admission reconciliation)
- Polyethylene glycol daily; last bowel movement charted 36 hours ago
- Ondansetron 4 mg IV PRN — one dose 0700 for nausea
- 0800: T 36.8 °C, HR 88, BP 128/74, RR 16, SpO2 98% room air
- 1200: T 37.4 °C, HR 102, BP 138/80, RR 18
- 1500: T 38.6 °C, HR 118, BP 146/86, RR 20; skin hot, flushed, dry
- Intake 600 mL oral; output 0 mL urine since 0600
- 78-year-old with functional bowel/IBS and BPH; lives alone; ambulates with walker
- Home meds: dicyclomine 20 mg QID (continued inpatient), tamsulosin, occasional diphenhydramine for sleep
- No glaucoma per chart; no myasthenia gravis
- Unit corridor warm (28 °C) due to HVAC repair—patient room fan in use
- 1500: Patient picking at sheets; oriented to person only; says “mouth is cotton”
- Abdomen distended, hypoactive bowel sounds; denies flatus; bladder scan 450 mL
- Pupils 5 mm, sluggish reaction; denies sweating despite fever
- Cramping unchanged since admission—concern shifted to anticholinergic toxicity not IBS flare
Answer key & rationale
Frequently asked questions
Why is anticholinergic toxicity the main nursing concern with dicyclomine?
Dicyclomine is an antimuscarinic antispasmodic. In clinical trials at 160 mg daily, about 61% of patients reported anticholinergic-type adverse events. Nurses must watch for dry mouth, urinary retention, constipation, confusion or delirium (especially in older adults), tachycardia, blurred vision, and decreased sweating with fever or heat stroke in hot environments. Stacking with other anticholinergics increases risk.
When should nurses hold dicyclomine?
Hold and contact the prescriber or pharmacist for contraindications (infants under 6 months, breastfeeding, glaucoma, myasthenia gravis, obstructive GI or urinary disease, severe ulcerative colitis, reflux esophagitis, unstable cardiovascular status in acute hemorrhage), suspected anticholinergic toxicity, or if efficacy is not achieved and side effects require doses below 80 mg per day after two weeks per labeling.
What is the usual adult oral dicyclomine dosing?
The recommended initial oral dose is 20 mg four times daily. After one week, the dose may be increased to 40 mg four times daily unless side effects limit escalation. Discontinue if efficacy is not achieved or if side effects require doses less than 80 mg per day after two weeks.
Is there a specific antidote for dicyclomine overdose?
Overdose signs include headache, nausea, vomiting, blurred vision, dilated pupils, hot dry skin, dizziness, dry mouth, difficulty swallowing, and CNS stimulation including convulsions; neuromuscular blockade may occur. Treatment includes gastric lavage, emetics, activated charcoal, and sedatives for excitement. If indicated, an appropriate parenteral cholinergic agent may be used as an antidote per U.S. prescribing information.
Can patients breastfeed while taking dicyclomine?
Dicyclomine is contraindicated in nursing mothers per U.S. prescribing information because it is excreted in human milk and serious adverse reactions are possible in breast-fed infants. LactMed advises against use during lactation and notes a possible case of apnea in a breastfed infant. A decision should weigh maternal need against infant risk with the care team.
References
-
U.S. National Library of Medicine. DICYCLOMINE HYDROCHLORIDE tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3713ae82-f36d-4491-9978-3111599ceafb
-
Drugs and Lactation Database (LactMed). Dicyclomine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501454/
-
National Library of Medicine. MedlinePlus: Dicyclomine.https://medlineplus.gov/druginfo/meds/a684007.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.